Discontinued — last reported Q4 '25
Snowflake Acquisitions remained flat by 0.0% to $44.71M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 239.2%, from $13.18M to $44.71M.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $177.93M | $0.00 | $174.63M | $10.05M | $123.11M | $141.46M | $14.96M | $0.00 | $0.00 | $8.91M | $8.22M | $13.18M | $44.71M | $44.71M | $44.71M | $44.71M |
| QoQ Change | — | — | — | — | — | -100.0% | — | -94.2% | >999% | +14.9% | -89.4% | -100.0% | — | — | -7.7% | +60.4% | +239.2% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | — | — | — | — | -30.8% | — | -91.4% | -100.0% | -100.0% | -93.7% | -45.1% | — | — | +402.0% | +444.0% | +239.2% |